1030 related articles for article (PubMed ID: 25896035)
1. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
2. Expression of α-synuclein is regulated in a neuronal cell type-dependent manner.
Taguchi K; Watanabe Y; Tsujimura A; Tanaka M
Anat Sci Int; 2019 Jan; 94(1):11-22. PubMed ID: 30362073
[TBL] [Abstract][Full Text] [Related]
3. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders.
Ono K; Hirohata M; Yamada M
Curr Pharm Des; 2008; 14(30):3247-66. PubMed ID: 19075704
[TBL] [Abstract][Full Text] [Related]
5. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve.
Uemura N; Yagi H; Uemura MT; Hatanaka Y; Yamakado H; Takahashi R
Mol Neurodegener; 2018 May; 13(1):21. PubMed ID: 29751824
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
7. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
[TBL] [Abstract][Full Text] [Related]
8. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
9. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.
Jellinger KA
Biochim Biophys Acta; 2009 Jul; 1792(7):730-40. PubMed ID: 18718530
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
Sarkar S; Raymick J; Imam S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
Orimo S
Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
[TBL] [Abstract][Full Text] [Related]
13. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
[TBL] [Abstract][Full Text] [Related]
15. What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut?
Kujawska M; Jodynis-Liebert J
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424585
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
Henderson MX; Trojanowski JQ; Lee VM
Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
[TBL] [Abstract][Full Text] [Related]
17. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
Oueslati A
J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
[TBL] [Abstract][Full Text] [Related]
18. Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies.
Fleming SM; Davis A; Simons E
Neuropharmacology; 2022 Jan; 202():108870. PubMed ID: 34742741
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
20. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.
Hartlage-Rübsamen M; Bluhm A; Moceri S; Machner L; Köppen J; Schenk M; Hilbrich I; Holzer M; Weidenfeller M; Richter F; Coras R; Serrano GE; Beach TG; Schilling S; von Hörsten S; Xiang W; Schulze A; Roßner S
Acta Neuropathol; 2021 Sep; 142(3):399-421. PubMed ID: 34309760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
